FDA Accepts Koutif Therapeutics’ Investigational New Drug Application for KT-1002
News
The U.S. Food and Drug Administration (FDA) has accepted Koutif Therapeutics’ investigational new drug (IND) application for KT-1002. The company is set to begin a Phase 1 clinical trial testing the experimental therapy in inflammatory bowel ... Read more